Key result
LVM regression on nocturnal hemodialysis is linked to substantially lower FGF23 levels vs progressors.
Why the study?
Dysregulation of the FGF23/Klotho axis is implicated in uremic cardiomyopathy in ESKD patients, but the mechanism linking dialysis intensity to the regulation of this pathway remained poorly defined.
Does transitioning to nocturnal hemodialysis regulate the FGF23-Klotho pathway via miRNAs to mitigate adverse cardiac remodeling and reduce left ventricular mass in ESKD patients?
Cohort (n=13)
Does transitioning to nocturnal hemodialysis regulate the FGF23-Klotho pathway via miRNAs to mitigate adverse cardiac remodeling and reduce left ventricular mass in ESKD patients?
This translational study provides a mechanistic basis for the cardiovascular benefits of nocturnal hemodialysis by linking dialysis intensification to miRNA-mediated suppression of the FGF23/Klotho axis and attenuation of pathological cardiac remodeling.
Answers are grounded in this paper and cite their sources.
Supports hypothesis that FGF23/miRNA modulation underlies LVM benefits of nocturnal hemodialysis; leaves open confirmation in larger randomized studies.
Background: Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality in patients with ESKD. Dysregulation of the fibroblast growth factor 23 (FGF23)/Klotho axis has been implicated in uremic cardiomyopathy, however the mechanism linking dialysis intensity to the regulation of this pathway remains poorly defined. Methods: We analyzed serum samples from ESKD patients transitioning from conventional to nocturnal hemodialysis (NHD). Left ventricular mass (LVM) was measured by echocardiography before and after transition. Patients were stratified as LVM regressors [ ≥ 10% decrease in LVM; n = 6] or LVM progressors [ ≥ 10% increase in LVM; n = 7]. Circulating microRNAs (miRs) and serum FGF23 and alpha Klotho were quantified. Mechanistic relevance was tested in an angiotensin-II model of cardiac hypertrophy using FGF23 suppression via an antisense oligonucleotide gapmer, or antagomirs targeting miR-200c-3p. Results: Among 13 patients transitioning to NHD, LVM regressors required fewer antihypertensive medications than at baseline (P<0.001) with improved metabolic parameters (urea 12.9 vs. 16.6 mmol/L, P<0.01) and higher hemoglobin (109 vs. 95 g/L, P<0.01). We identified six differentially expressed miRs (let-7a/g/i, miR-200c, miR-1 and miR-30c) that targeted the FGF23/Klotho signaling axis. LVM regressors also demonstrated significantly lower circulating FGF23 levels than LVM progressors [60 (28, 160) vs 668 (73, 1734) pg/mL, P<0.05]. In the angiotensin-II murine model of cardiac hypertrophy, FGF23 gapmer treatment or miR-200c-3p inhibition reduced cardiomyocyte hypertrophy and attenuated interstitial fibrosis while restoring FGF23/Klotho signaling through the suppression of extracellular signal-regulated kinase 1/2 phosphorylation, activation of dual specificity phosphatase-1 and inducing antioxidant gene expression. Conclusions: Collectively, these exploratory findings link dialysis intensification to miR-mediated regulation of the FGF23/Klotho axis, demonstrating that targeting this regulatory network is sufficient to suppress pathological cardiac remodeling. These data provide a mechanistic basis for the cardiovascular benefits of nocturnal hemodialysis and identify the FGF23/Klotho axis as a candidate therapeutic target warranting further validation.
No takes yet. Share an insight, caveat, or question.
Alberga et al. (2026) conducted a cohort in End-stage kidney disease (ESKD) transitioning to nocturnal hemodialysis, plus an angiotensin-II murine model of cardiac hypertrophy (n=13). Transition to nocturnal hemodialysis (and FGF23 gapmer or miR-200c-3p antagomir in mice) vs. LVM progressors (>=10% increase in LVM) / baseline conventional hemodialysis was evaluated on Circulating FGF23 levels and left ventricular mass (LVM) regression (p=<0.05). Nocturnal hemodialysis patients with LVM regression had lower circulating FGF23 levels than LVM progressors and differential miRNA expression targeting FGF23/Klotho.
Synapse has enriched 10 related papers. Consider them for comparative context: